Polymer-protein-enhanced fluoroimmunoassay for prostate-specific antigen

Area of Science:

• Biochemistry
• Analytical Chemistry
• Oncology

Background:

• Prostate-specific antigen (PSA) is a biomarker for prostate cancer, existing as free and complexed forms.
• Current Enzyme-linked immunosorbent assay (ELISA) methods for PSA detection have limitations in sensitivity and detection limits.
• The free to total PSA ratio is crucial for prostate cancer diagnosis, with a ratio of 0.25 often indicative of cancer.

Purpose of the Study:

• To evaluate the ALYGNSA system for improved detection of free and total PSA.
• To assess the potential of enhanced PSA detection for definitive cancer diagnosis.

Main Methods:

• Determination of detection limits for free and total PSA using commercial ELISA kits.
• Implementation of the ALYGNSA fluorescent assay system with a selective polymer biolinker.
• Measurement of free and total PSA detection limits and the free to total PSA ratio using the ALYGNSA system.

Main Results:

• Commercial ELISA kits had detection limits of 1 ng/mL for free PSA and 10 ng/mL for total PSA.
• The ALYGNSA system achieved significantly lower detection limits: 0.13 ng/mL for free PSA and 0.63 ng/mL for total PSA.
• This represents an 8-fold improvement for free PSA and a 15-fold improvement for total PSA detection.

Conclusions:

• The ALYGNSA system offers a substantial improvement in sensitivity and detection limits for free and total PSA.
• The enhanced detection capabilities may lead to more definitive diagnosis of prostate cancer and potentially other cancers.
• A free to total PSA ratio of 0.20 was maintained, suggesting its utility in diagnostic applications.